Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

I don't normally write about immediate news in medicine and science, after all, that's what the news wires are for, but one item caught my eye this morning… 'Refractory Inflammatory Breast Cancer May Respond to Lapatinib'.

Essentially, GSK's lapatinib
(Tykerb) yielded tumor responses in 39% of women with HER2+ inflammatory breast
cancer heavily pretreated with chemotherapy, including trastuzumab
(Herceptin).  The phase II trial has been reported in The Lancet.

These patients typically have a poorer prognosis, so one wouldn't
expect much of a response, but almost 40% in a difficult to treat group
of patients is quite dramatic.  What was even more interesting was the
lapatinib responses lasted an average of 20.9 weeks with a
progression-free survival of 14.9 weeks, a very good clinical response
indeed, suggesting use of the therapy earlier, ie upfront, may lead to
hopefully longer responses; time will tell, but the initial results are promising so far.

ResearchBlogging.org
Kaufman, B., Trudeau, M., Awada, A., Blackwell, K., Bachelot, T., Salazar, V., DeSilvio, M., Westlund, R., Zaks, T., & Spector, N. (2009).  Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study The Lancet Oncology DOI: 10.1016/S1470-2045(09)70087-7

Reblog this post [with Zemanta]

2 Responses to “Cancer drug effective in inflammatory breast cancer?”

  1. Breast cancer drug

    Abraxane is the nanotechnology breast cancer drug, developed by Abraxis BioScience. It is widely advertised in United States. In 2005, the U.S. FDA approved the use of Abraxane in Injectable Suspension for breast cancer treatment taking into consideration its side effects, post the not so desirable effects of chemotherapy.

  2. Kia Ren

    Pathology.org is the largest up to date informational database consisting of general health and disease information. The only way to combat disease and promote healthy living is to provide the public current information on health and diseases. Pathology.org consists of breaking news in the health world and offers the information needed to take preventive and combative measures to fight disease. Your website seems to be a very credible resource and would beneficial to us in the fight to combat the contraction and spread of disease. You can aid us in this fight by simply putting a banner or link up for us, making our site available to your vast public. I have included the code for the banner within this email showing you exactly what this banner will look like. Thank you for your time, effort, and work you have done, we look forward to any thoughts you may have.

Comments are closed.

error:
error: Content is protected !!